UY33265A - Composiciones sólidas que comprenden (2R, 6S, 13aS, 14aR, 16aS,z)-N-(ciclopropilsulfonil)-6-(5-metilpirazin-2-carboxamido)-5, 16-dioxo-2-(fenantridin-6-iloxi)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecin-14a-carboxamida para su uso como inhibidores del HCV y proceso para su preparación - Google Patents
Composiciones sólidas que comprenden (2R, 6S, 13aS, 14aR, 16aS,z)-N-(ciclopropilsulfonil)-6-(5-metilpirazin-2-carboxamido)-5, 16-dioxo-2-(fenantridin-6-iloxi)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecin-14a-carboxamida para su uso como inhibidores del HCV y proceso para su preparaciónInfo
- Publication number
- UY33265A UY33265A UY0001033265A UY33265A UY33265A UY 33265 A UY33265 A UY 33265A UY 0001033265 A UY0001033265 A UY 0001033265A UY 33265 A UY33265 A UY 33265A UY 33265 A UY33265 A UY 33265A
- Authority
- UY
- Uruguay
- Prior art keywords
- diazacyclopentadecin
- hexadecahydrocyclopropa
- pirrolo
- phenanthridin
- methylpyrazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Peptides Or Proteins (AREA)
Abstract
Composiciones sólidas que comprenden el compuestos I amorfo. Una dispersión sólida de la presente invención también contiene un polímero hidrofílico farmacéuticamente aceptable y un agente tensioactivo farmacéuticamente aceptable. El compuesto I puede formularse en una dispersión sólida amorfa que comprende un polímero hidrofílico farmacéuticamente aceptable, y preferiblemente un agente tensioactivo farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33996410P | 2010-03-10 | 2010-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33265A true UY33265A (es) | 2011-10-31 |
Family
ID=44564075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033265A UY33265A (es) | 2010-03-10 | 2011-03-09 | Composiciones sólidas que comprenden (2R, 6S, 13aS, 14aR, 16aS,z)-N-(ciclopropilsulfonil)-6-(5-metilpirazin-2-carboxamido)-5, 16-dioxo-2-(fenantridin-6-iloxi)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecin-14a-carboxamida para su uso como inhibidores del HCV y proceso para su preparación |
Country Status (27)
Country | Link |
---|---|
US (1) | US20110312973A1 (es) |
EP (1) | EP2544689B1 (es) |
JP (2) | JP5717768B2 (es) |
KR (1) | KR101579079B1 (es) |
CN (2) | CN104771364B (es) |
AR (1) | AR081736A1 (es) |
AU (1) | AU2011224558B2 (es) |
BR (1) | BR112012022774A2 (es) |
CA (1) | CA2792601C (es) |
CL (1) | CL2012002500A1 (es) |
CO (1) | CO6640208A2 (es) |
DO (1) | DOP2012000245A (es) |
EA (1) | EA021570B1 (es) |
EC (1) | ECSP12012148A (es) |
ES (1) | ES2613608T3 (es) |
GT (1) | GT201200257A (es) |
IL (1) | IL221833A (es) |
MX (1) | MX2012010478A (es) |
MY (1) | MY156888A (es) |
NZ (1) | NZ602288A (es) |
PE (1) | PE20130198A1 (es) |
SG (1) | SG183985A1 (es) |
TW (1) | TWI490218B (es) |
UA (1) | UA104517C2 (es) |
UY (1) | UY33265A (es) |
WO (1) | WO2011112558A2 (es) |
ZA (1) | ZA201207093B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE049986T2 (hu) * | 2010-07-12 | 2020-11-30 | Salix Pharmaceuticals Inc | Rifaximin készítmények és ezek alkalmazásai |
CN103380132B (zh) * | 2010-12-30 | 2016-08-31 | 益安药业 | 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂 |
US9044480B1 (en) | 2011-03-03 | 2015-06-02 | Abbvie Inc. | Compositions and methods for treating HCV |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
CA2847355A1 (en) * | 2011-09-16 | 2013-03-21 | Abbvie Inc. | Methods for treating hcv |
AU2015200715A1 (en) * | 2011-10-21 | 2015-03-05 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
AU2015100285B4 (en) * | 2011-10-21 | 2015-06-11 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
UY34402A (es) | 2011-10-21 | 2013-05-31 | Abbvie Inc | Métodos para el tratamiento de hcv |
AU2013201758B2 (en) * | 2011-10-21 | 2014-11-27 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333) |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
ES2572355B1 (es) * | 2011-10-21 | 2017-08-24 | Abbvie Inc. | Combinación de aad para uso en el tratamiento del vhc |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
CN104379145A (zh) | 2012-06-27 | 2015-02-25 | 艾伯维公司 | Abt-450和利托那韦和例如abt-072和/或abt-333用于在治疗hcv中使用的联合治疗 |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
CN104603138A (zh) * | 2012-07-12 | 2015-05-06 | 艾伯维公司 | Hcv抑制剂的晶形 |
CN109897004A (zh) * | 2012-09-11 | 2019-06-18 | 麦迪威森***医疗有限责任公司 | 恩杂鲁胺制剂 |
LT2909205T (lt) | 2012-10-19 | 2016-12-27 | Bristol-Myers Squibb Company | 9-metilpakeistieji heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4)diazaciklopentadecinilkarbamato dariniai, kaip nestruktūrinės 3 (ns3) proteazės inhibitoriai, skirti hepatito c viruso infekcijų gydymui |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CN105164148A (zh) | 2013-03-07 | 2015-12-16 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
EA029088B1 (ru) | 2013-03-15 | 2018-02-28 | Джилид Сайэнс, Инк. | Макроциклические и бициклические ингибиторы вируса гепатита c |
MX2015017953A (es) | 2013-07-02 | 2016-10-28 | Abbvie Inc | Metodos para tratar el virus de hepatitis c. |
WO2015038596A1 (en) | 2013-09-11 | 2015-03-19 | Emory University | Nucleotide and nucleoside compositions and uses related thereto |
US20150141351A1 (en) * | 2013-11-18 | 2015-05-21 | AbbVie Deutschland GmbH & Co. KG | Solid Pharmaceutical Compositions |
US20150175612A1 (en) * | 2013-12-04 | 2015-06-25 | Abbvie Inc. | Crystal forms |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
WO2015116594A1 (en) | 2014-01-28 | 2015-08-06 | Abbvie Inc. | Dose adjustment in combination therapy of hepatitis c |
CN106456556A (zh) * | 2014-06-18 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 包含非离子性表面活性剂的新型药物组合物 |
US20160074462A1 (en) | 2014-09-11 | 2016-03-17 | Abbvie Inc. | Method of Treating HCV |
WO2016134058A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Combinations useful to treat hepatitis c virus |
US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
MX2018002462A (es) * | 2015-08-28 | 2018-06-19 | Caliway Biopharmaceuticals Co Ltd | Una composicion farmaceutica para reducir la grasa localizada y sus usos. |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
JP7027412B2 (ja) | 2016-09-30 | 2022-03-01 | サリックス ファーマスーティカルズ,インコーポレーテッド | リファキシミンの固体分散体の形態 |
KR102306138B1 (ko) | 2017-03-15 | 2021-09-28 | 세레신 인코포레이티드 | 고 약물 부하량의 중쇄 트리글리세라이드를 갖는 약학 조성물 및 이와 관련된 방법 |
US10004719B1 (en) | 2017-05-30 | 2018-06-26 | Taigen Biotechnology Co., Ltd. | Solid dispersion formulation |
CN113164403A (zh) * | 2018-11-30 | 2021-07-23 | 凯莫森特里克斯股份有限公司 | 胶囊制剂 |
WO2023154171A1 (en) * | 2022-02-14 | 2023-08-17 | Purdue Research Foundation | Polymer salts for improved drug delivery from amorphous solid dispersions |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
RS20050741A (en) * | 2003-04-02 | 2007-06-04 | Boehringer Ingelheim International Gmbh., | Pharmaceutical compositions for hepatitis c viral protease inhibitors |
US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
CN1274300C (zh) * | 2003-12-11 | 2006-09-13 | 中国科学院生物物理研究所 | 用于改善姜黄素溶出度和生物利用度的药物组合物及其制备方法 |
US20060068007A1 (en) * | 2004-09-24 | 2006-03-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | Class of surfactant-like materials |
TW200716631A (en) * | 2005-05-12 | 2007-05-01 | Tibotec Pharm Ltd | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof |
JP5426164B2 (ja) * | 2005-07-29 | 2014-02-26 | ヤンセン・アールアンドデイ・アイルランド | C型肝炎ウイルスの大環式インヒビター |
PE20080992A1 (es) * | 2006-06-26 | 2008-08-06 | Enanta Pharm Inc | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c |
EP1880715A1 (en) * | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
CN101903391B (zh) * | 2007-12-21 | 2013-04-03 | 弗·哈夫曼-拉罗切有限公司 | 大环化合物的制备方法 |
MX2010011306A (es) * | 2008-04-15 | 2010-11-09 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c. |
AR072991A1 (es) * | 2008-08-07 | 2010-10-06 | Schering Corp | Formulaciones farmaceuticas de un inhibidor de la enzima proteasa de hcv en una dispersion molecular solida |
UY32099A (es) * | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
EP2346329B1 (en) * | 2008-10-09 | 2013-08-21 | Anadys Pharmaceuticals, Inc. | A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
US8476225B2 (en) * | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
-
2011
- 2011-03-08 CN CN201510101125.8A patent/CN104771364B/zh not_active Expired - Fee Related
- 2011-03-08 KR KR1020127026358A patent/KR101579079B1/ko active Protection Beyond IP Right Term
- 2011-03-08 UA UAA201211694A patent/UA104517C2/uk unknown
- 2011-03-08 SG SG2012066924A patent/SG183985A1/en unknown
- 2011-03-08 JP JP2012557164A patent/JP5717768B2/ja active Active
- 2011-03-08 CA CA2792601A patent/CA2792601C/en not_active Expired - Fee Related
- 2011-03-08 NZ NZ602288A patent/NZ602288A/en not_active IP Right Cessation
- 2011-03-08 US US13/042,805 patent/US20110312973A1/en not_active Abandoned
- 2011-03-08 WO PCT/US2011/027511 patent/WO2011112558A2/en active Application Filing
- 2011-03-08 AU AU2011224558A patent/AU2011224558B2/en not_active Ceased
- 2011-03-08 BR BR112012022774A patent/BR112012022774A2/pt active Search and Examination
- 2011-03-08 EP EP11753907.2A patent/EP2544689B1/en active Active
- 2011-03-08 PE PE2012001536A patent/PE20130198A1/es active IP Right Grant
- 2011-03-08 ES ES11753907.2T patent/ES2613608T3/es active Active
- 2011-03-08 MY MYPI2012700621A patent/MY156888A/en unknown
- 2011-03-08 CN CN201180023346.8A patent/CN103118681B/zh not_active Expired - Fee Related
- 2011-03-08 EA EA201290892A patent/EA021570B1/ru not_active IP Right Cessation
- 2011-03-08 MX MX2012010478A patent/MX2012010478A/es active IP Right Grant
- 2011-03-09 UY UY0001033265A patent/UY33265A/es not_active Application Discontinuation
- 2011-03-10 AR ARP110100756A patent/AR081736A1/es unknown
- 2011-03-10 TW TW100108152A patent/TWI490218B/zh not_active IP Right Cessation
-
2012
- 2012-09-07 DO DO2012000245A patent/DOP2012000245A/es unknown
- 2012-09-09 IL IL221833A patent/IL221833A/en not_active IP Right Cessation
- 2012-09-10 CO CO12154969A patent/CO6640208A2/es not_active Application Discontinuation
- 2012-09-10 EC ECSP12012148 patent/ECSP12012148A/es unknown
- 2012-09-10 CL CL2012002500A patent/CL2012002500A1/es unknown
- 2012-09-10 GT GT201200257A patent/GT201200257A/es unknown
- 2012-09-20 ZA ZA2012/07093A patent/ZA201207093B/en unknown
-
2015
- 2015-03-16 JP JP2015051690A patent/JP5890553B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33265A (es) | Composiciones sólidas que comprenden (2R, 6S, 13aS, 14aR, 16aS,z)-N-(ciclopropilsulfonil)-6-(5-metilpirazin-2-carboxamido)-5, 16-dioxo-2-(fenantridin-6-iloxi)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecin-14a-carboxamida para su uso como inhibidores del HCV y proceso para su preparación | |
CL2011000301A1 (es) | Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer. | |
CL2011000512A1 (es) | (2r,6s,13as,14ar,16as,z)-n- (ciclopropilsulfonil)-6-(5-metilpirazin-2-carboxamido)-5,16-dioxo-2-(fenantridin-6-iloxi)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecin-14a-carboxamida y composicion farmaceutica que lo comprende. | |
CO6551708A2 (es) | Procedimiento para la preparaci´n de {4.6- diamino-2-[1-(2- fluorobencil)-1h- pirazolo[3.4-b] piridin -3-il-]pirimidin -5-il} metilcarbamato de metilo y su purificación para su uso como principio famacéutico | |
BR112012012529A2 (pt) | composto indol e seu uso farmacêutico | |
AR077144A1 (es) | Derivado de fenilimidazol como inhibidor de la enzima pde10a, composiciones farmaceuticas y uso de los mismos en el tratamiento de trastornos neurodegenerativos y psiquiatricos | |
CL2008001274A1 (es) | Compuestos macrolidos derivados de 5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropan[e]pirrolo[1,2-a][1,4]diazaciclopentadecinilo, inhibidores de la actividad de la proteasa ns3-ns4; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios y procedimiento de preparacion; y uso en el tratamiento de..... | |
CL2012001807A1 (es) | Compuestos derivados de naftiridina, inhibidores de syk quinasa; compuestos intermediarios, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades tales como rinitis alergica, asma, epoc, lupus eritematoso, urticaria/angioedema, entre otros. | |
UY31673A1 (es) | "derivados heterocíclicos de urea y métodos de uso de los mismos-211" | |
GT201300180A (es) | "compuesto de imidazo (4,5-c) quinolin-2-ona y su uso como inhibidor dual de cinasa pi3/mtor" | |
CL2008001745A1 (es) | Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer. | |
CO6321259A2 (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina su uso como inhibidores de mtor quinasa y pi3 quinasa y su sintesis | |
NI201100062A (es) | Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38. | |
ECSP12012104A (es) | Inhibidores de virus flaviviridae | |
CL2012000163A1 (es) | Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras. | |
WO2013128028A8 (en) | Pyrazolo-triazine derivatives as selective cyclin- dependent kinase inhibitors | |
CL2011002180A1 (es) | Compuestos derivados de benzimidazol, inhibidores de mpges-1; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y dolor. | |
CL2011002056A1 (es) | Compuestos derivados del acido {7-([1,2,3]triazol-1-il)-6,7,8,9-tetrahidropirido[1,2-a]indol-10-il}-acetico, antagonista del receptor crth2; composicion farmaceutica que lo comprende; utiles ene l tratamiento del asma, alergias, cancer entre otras. | |
CL2015001342A1 (es) | Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer. | |
CL2013001591A1 (es) | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. | |
CL2013002003A1 (es) | Compuestos derivados de 1, 2, 4-triazolo [4,3-a] quinoxalina, inhibidores de pde2 y/o 10; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para en el trastamiento de enfermedades del snc | |
CL2014000641A1 (es) | Compuestos derivados de triazolo[1,5-a]piridina, inhibidores de la ped10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como esquizofrenia, parkinson, alzheimer, entre otras. | |
CL2012002887A1 (es) | Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer. | |
BR112014001665A2 (pt) | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz | |
CO6551707A2 (es) | Procedimiento para la preparaciçon de {4.6-diamino-2[1-2(2-fluorobencil)-1h- pirazolo [3.4-b]piridin -3-il] pirimidin -5-il} carbamato de metilo y su purificación para el uso como principio activo farmacéutico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20211006 |